GLP-1 Dosing Regimen for Short Half-Life and Side-Effect Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing GLP-1 analogs have a short half-life due to rapid degradation by DPP4, limiting their efficacy in treating diabetes, obesity, and overweight, and there is a need for improved dosing regimens to enhance therapeutic effects while minimizing side effects.
Innovation Solution
A dosing regimen involving continuous administration of beinaglutide at varying doses and timing relative to meals, combined with additional active ingredients like insulin and metformin, to optimize therapeutic outcomes for diabetes, obesity, and overweight.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If GLP-1 analogs are administered to treat diabetes and obesity, then therapeutic efficacy is improved, but the short half-life due to rapid DPP4 degradation limits sustained effectiveness
Solution Approach 1:
The patent employs periodic dosing regimens where GLP-1 analogs are administered at specific intervals (e.g., before meals or at set times throughout the day) to maintain therapeutic levels despite rapid degradation. This periodic administration compensates for the short half-life by ensuring consistent drug presence in the system during critical periods for glucose control and satiety.
Solution Approach 2:
The patent utilizes dose escalation strategies where the dosage is gradually increased over time (e.g., starting at lower doses and titrating upward) to achieve optimal therapeutic effect while managing the short half-life constraint. This parameter change approach allows the body to adapt and maintains efficacy despite rapid drug clearance.
2Reliability
If higher doses of GLP-1 analogs are administered to enhance therapeutic effect, then efficacy in treating diabetes and obesity is improved, but side effects increase
Solution Approach 1:
The patent applies partial action by administering GLP-1 analogs at doses that are sufficient to achieve therapeutic benefits for specific indications (diabetes control, weight management) without exceeding the threshold that triggers significant side effects. The dosing is calibrated to provide just enough pharmacological effect needed for each indication.
Solution Approach 2:
The patent employs dynamic dosing regimens where the dosage and timing are adjusted based on individual patient responses, meal patterns, and glycemic control needs. This dynamic approach allows optimization of efficacy while minimizing side effects by adapting the treatment to the patient's physiological state rather than using fixed high doses.
3Duration of action of stationary object
If multiple dosing administrations are given throughout the day to maintain therapeutic levels, then sustained efficacy is improved, but treatment complexity increases
Solution Approach 1:
The patent structures multiple dosing administrations around periodic cycles related to daily meal patterns (e.g., before breakfast, lunch, and dinner) or fixed time intervals. This periodic structure makes the complex multi-dose regimen more manageable and easier to remember compared to arbitrary dosing schedules.
Solution Approach 2:
The patent designs dosing regimens that serve multiple functions simultaneously - for example, administering GLP-1 analogs at meal times not only maintains therapeutic levels for diabetes control but also leverages the satiety effect at appropriate moments, and provides consistent glucose control throughout the day. This multi-functionality reduces the need for separate dosing events.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The regimen significantly decreases HbA1c and body weight in subjects, demonstrating improved efficacy and reduced side effects compared to traditional administration methods.
Implementation Method 1
Upon entry into circulation, GLP-1 is rapidly degraded by dipeptidyl peptidase-4 (DPP4), resulting in a short half-life of about 2 minutes.
Data Source
AI summary
Disclosed herein are dosing regimens of GLP-1 and/or GLP-1 analog (s).